Protagonist Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 7, 2024
PTGX$136.26+0.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In thousands, except share and per share data)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · March 31, · · December 31, | ||||||
| | 2024 | 2023 | ||||
| Assets | | | | | | |
| Current assets: | | | | | | |
| Cash and cash equivalents | | $172,568 | | $186,727 | ||
| Marketable securities | | | 150,067 | | | 154,890 |
| Receivable from collaboration partner | | | 300,043 | | | 10,000 |
| Prepaid expenses and other current assets | | | 4,875 | | | 3,960 |
| Total current assets | | | 627,553 | | | 355,577 |
| Property and equipment, net | | | 1,111 | | | 1,195 |
| Restricted cash - noncurrent | | | 225 | | | 225 |
| Operating lease right-of-use asset | | | 387 | | | 954 |
| Total assets | | $629,276 | | $357,951 | ||
| Liabilities and Stockholders’ Equity | | | | | | |
| Current liabilities: | | | | | | |
| Accounts payable | | $3,507 | | $772 | ||
| Payable to collaboration partner | | | 3 | | | 3 |
| Accrued expenses and other payables | | | 16,487 | | | 19,358 |
| Deferred revenue - current | | | 16,125 | | | — |
| Income taxes payable | | | 3,326 | | | — |
| Operating lease liability - current | | | 462 | | | 1,141 |
| Total current liabilities | | | 39,910 | | | 21,274 |
| Deferred revenue - noncurrent | | | 28,922 | | | — |
| Total liabilities | | | 68,832 | | | 21,274 |
| Commitments and contingencies | | | | | | |
| Stockholders’ equity: | | | | | | |
| Preferred stock, $0.00001 par value, 10,000,000 shares authorized; no shares issued and outstanding | | | — | | | — |
| Common stock, $0.00001 par value, 90,000,000 shares authorized; 58,600,787 and 57,708,613 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively | | | 1 | | | 1 |
| Additional paid-in capital | | | 969,042 | | | 952,491 |
| Accumulated other comprehensive loss | | | (229) | | | (105) |
| Accumulated deficit | | | (408,370) | | | (615,710) |
| Total stockholders’ equity | | | 560,444 | | | 336,677 |
| Total liabilities and stockholders’ equity | | $629,276 | | $357,951 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.